Pharmacogenetic Study on Risperidone Long-Acting Injection-Reference-Cited by-同舟云学术

Pharmacogenetic Study on Risperidone Long-Acting Injection

Published:2013-06 Issue:3 Volume:33 Page:289-298
ISSN:0271-0749
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Choong Eva,Polari Andrea,Kamdem Rigobert Hervais,Gervasoni Nicola,Spisla Caesar,Sirot Eveline Jaquenoud,Bickel Graziella Giacometti,Bondolfi Guido,Conus Philippe,Eap Chin B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference36 articles.

1. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.;Spina;Psychopharmacology (Berl),2001

2. Prolactin levels and adverse events in patients treated with risperidone.;Kleinberg;J Clin Psychopharmacol,1999

3. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.;Bondolfi;Pharmacopsychiatry,2002

4. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.;Spina;Ther Drug Monit,2001

5. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.;Jung;Clin Pharmacol Ther,2005

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond One-Size-Fits-All: Personalized Medicine and Future Directions in Sex-Based Psychopharmacological Treatment;Future Pharmacology;2024-08-20

2. Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review;Journal of Psychiatric Research;2024-06

3. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations;Expert Opinion on Drug Metabolism & Toxicology;2023-04-03

4. Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives;Journal of Personalized Medicine;2023-02-22

5. Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation;Clinical Infectious Diseases;2022-11-21